GlassScriptPhysician profile
Mandi Battles
NPI 1538398870
$8,233.84
in general payments reported to CMS, 2019-2025
26 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $202 · 2023: $1,465 · 2024: $4,105 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,294 · Consulting Fee: $1,140 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,294.11 |
| Consulting Fee | $1,140.00 |
| Education | $398.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,663.19 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,582.09 | 2023-2025 | |
| Lilly USA, LLC | $1,167.48 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $848.47 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $380.06 | 2023-2025 | Adbry |
| Genzyme Corporation | $364.61 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $335.10 | 2024-2025 | Dupixent |
| Incyte Corporation | $325.61 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $306.40 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $230.69 | 2023-2025 | Jublia, Siliq, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $188.73 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $187.39 | 2025 | Nemluvio |
| Novo Nordisk INC | $162.91 | 2021-2023 | Ozempic |
| Novartis Pharmaceuticals Corporation | $145.69 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $68.00 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $63.82 | 2021 | |
| Dermavant Sciences, INC. | $38.68 | 2024 | Vtama |
| Bayer Healthcare Pharmaceuticals INC. | $29.27 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.22 | 2022 | |
| Pfizer INC. | $21.57 | 2022 | |
| Amgen INC. | $20.08 | 2024 | Otezla |
| Merck Sharp & Dohme LLC | $19.04 | 2021 | |
| Sanofi Pasteur INC. | $17.85 | 2023 | |
| Botanix Sb INC | $17.53 | 2025 | Sofdra |
| Dynavax Technologies Corporation | $14.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandi Battles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.